Diagnostic Advances in Metastatic Breast Cancer

-

I continue to be encouraged by advances in the use of circulating tumor cell (CTC) analysis in cancer treatment, but so much work needs to be done.  In a recent study led by Martine Mazel from University Medical Centre in Montpellier, France, researchers have demonstrated the ability to gauge PD-L1 expression from liquid biopsies of metastatic breast cancer patients.  Immune checkpoint regulators are becoming increasing important and have given rise to the development of immunotherapies for cancer treatment. PD-L1 is an immune checkpoint regulator targeted by a number of approved and developmental oncology therapies.  

Using the CELLSEARCH® System developed by Janssen Diagnostics, researchers tested blood samples from 16 women with hormone receptor-positive, HER2-negative metastatic breast cancer and found 11 patients had a subpopulation of CTCs with weak or strong PD-L1 expression. These results indicate that CTC analysis for PD-L1 expression is feasible and when confirmed, could open up the opportunity to predict response to certain therapies in future, larger studies using a blood test rather than tissue biopsy. In a research setting, the CELLSEARCH® System offers the ability to capture CTCs via a routine blood test. 

"I believe we have demonstrated that CTC characterization for PD-L1 expression is feasible using a CTC platform. This paves the way for the utilization of a CTC/PD-L1 assay in future clinical trials to explore whether it can stratify patients according to response, and potentially predict the efficacy of immune checkpoint blockade," commented study investigator Catherine Alix-Panabieres, Ph.D., Director of the Laboratory of Rare Human Circulating Cells, University Medical Centre of Montpellier, University of Montpellier EA2415, Montpellier, France.  

CTCs have the potential to allow real-time, dynamic monitoring of tumor characteristics without the need for repeated invasive biopsies. It was demonstrated earlier that CTC expression of key biomarkers such as HER21, IGFR2, c-MET3 and other proteins can be monitored successfully. This publication in Molecular Oncology underscores the potential of CELLSEARCH® CTC testing to also become an important tool in cancer immunotherapy. 

Yet according to a recent article in MIT Technology Review, “new diagnostics can find the DNA that drives a tumor, but evidence that they help patients is missing”. “You have tests coming to market that are sometimes proven and sometimes unproven,” says Tycho Peterson, an analyst at J.P. Morgan who tracks the industry. “Commercial activity is increasing very quickly.” He estimates $20 billion a year in tests globally by 2020, up from about $100 million today.  But we are a long way from the liquid biopsy being used to detect cancer before symptoms arise. All the more reason that the National Foundation for Cancer Research continues to support the work of Dr. Daniel Haber, Director of the Massachusetts General Hospital in Boston, and his collaborators.  We have continuously supported this important research since 2004, and I believe this ultimately will help patients across ALL CANCERS.

 

Popular posts from this blog

A Bowl of Gratitude

-
Image
I was introduced recently to Lynne Sarnoff-Christensen by her cousin, and my friend Jeffrey Cohen. You see, she makes pottery and well, more specifically she make “bowls of gratitude”. So of course, Jeffrey knew that I would hit it off with Lynne because he knows I live a life full of gratitude. Another friend, Keith Spiro said I just had to buy a bowl – so I did. The idea is to put notes in the bowl about things you are grateful for. So it’s my new thing. I’ve long been a fan of Shawn Achor and I’ve gotten into the habit of writing down things that I am grateful for. So this bowl of gratitude will be where I put my notes. And I will encourage my family to also add their notes to the bowl. We have a tradition on Thanksgiving to go around the table before we dig in to our meal, to share what we are thankful for. We shouldn’t just do this at Thanksgiving! When I called Lynne, she explained her philosophy and I get it: “You didn’t get from there to here without people believ...
Read more

The Power of Community: The White Ribbon Project

-
Image
The Greek meaning of evangelist is "bringing the good news." It's why I call my podcast the Research Evangelist Podcast. I love to share stories about people in life sciences who are doing amazing work to advance cancer research. And it's why The White Ribbon Project has captured my attention. The White Ribbon Project is a grassroots movement of lung cancer patients, advocates, clinicians, researchers friends and families with a mission to change the public perception of lung cancer by spreading awareness that anyone with lungs can get lung cancer. No one deserves lung cancer whether you smoked or not. But lung cancer is not just a smokers disease, as more and more people are getting lung cancer with no smoking history. The White Ribbon Project is proving that the power of a community that cares can be unleashed by individuals who wanted to make a difference - people that didn't set out to start a movement. It's because their story is so sincere and authentic...
Read more

Time to Move Beyond the Ribbons?

-
This past week, I had the pleasure of meeting Massachusetts Senator Ed Markey and Harvard Medical School Professor of Genetics, Dr. Fred Alt. They were both in Washington, DC for the presentation of the 2015 NFCR Szent-Györgyi Prize for Progress in Cancer Research, which was awarded to Dr. Alt and keynoted by Sen. Markey.   The common theme I heard from both of these distinguished leaders was captured in a Huffington Post article written by Sam Stein , who attended the event . Stein succinctly wrote that “U.S. Science has never been more imperiled”. He noted that the lack of funding for basic scientific research not only prevents new discoveries, but it also means that we are losing promising scientists whose work can’t get funded.    10 years ago, nearly a third of qualified research was funded by NIH.   Now that number is only 14% (actually even lower for oncology, near 9%).   As Sen. Markey said, “sadly, support for scientific research in our countr...
Read more